Dr. Thomas Balshi/Intilight
No verified ownership, offshore or transport links have been attached to this record yet.
Compliance Profile
"Public-record notice: Dr. Thomas Balshi/Intilight appears in official public record data. The record is informational and should be checked against the original publisher before legal, financial or counterparty decisions are made."
Banking Impact
This public record does not establish a banking prohibition. Any onboarding or transaction decision should use the original source, a verified identity match and the institution's applicable legal framework.
Legal Status
This is an informational public record, not a sanctions, exclusion or enforcement conclusion unless the page expressly identifies an official issuing authority and record.
Public source metadata
Source: FDA Warning Letters| Full Legal Name | Dr. Thomas Balshi/Intilight |
| Known aliases | Center for Drug Evaluation and Research | CDER / Finished Pharmaceuticals/Unapproved New Drug/Misbranded |
| Source datasets | FDA WARNING LETTERfda_warning_letters |
| Record status | Informational public record |
| Publishing authority | www.fda.gov |
| Identifiers | 2022-04-13 / Finished Pharmaceuticals/Unapproved New Drug/Misbranded |
| Record timeline | First seen: 2022-04-13 • Last seen: 2022-04-13 |
| Risk Topics | reg.action, reg.warn, sector.medical |
| Original source | View source record |
Compliance Context Review
Independent assessment
SIC Group prepares source-backed risk context, exposure memos, and remediation pathways for entities seeking to clarify a public record or counterparty signal.